UPCC 30818: A Phase 2 Open-Label Single-Arm Multicenter Study to Assess the Safety and Efficacy of ASP1650 a Monoclonal Antibody Targeting Claudin 6 (CLDN6) in Male Subjects with Incurable Platinum Refractory Germ Cell Tumors
Brief description of study
The goal of this study is to confirm that an investigational study drug, ASP1650, is both safe and effective as a treatment in participants with incurable, refractory germ cell tumors that have Claudin 6 (CLDN6) expression.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Incurable Platinum Refractory Germ Cell Tumors, Tumors
-
Age: - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 832068